CSTL
Castle Biosciences Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Castle Biosciences Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
+4.52%
vs ±15.4% implied · ×0.29
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Castle Biosciences Inc's 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Castle Biosciences Inc's 6 closest co-movers, 1 shares that code.
Castle Biosciences Inc
38.47
−0.04 · −0.11%
post 37.13 −3.48%
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $78.5M | 12.01% | +10.36% |
| RTW | $66.3M | 10.13% | +0.73% |
| Principal Financial | $41.2M | 6.30% | −2.44% |
| Vanguardindex-like | $29.3M | 4.47% | +4.16% |
| Acadian | $21.9M | 3.35% | +89.63% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $78.5M | 12.01% | +10.36% |
| RTW | $66.3M | 10.13% | +0.73% |
| Principal Financial | $41.2M | 6.30% | −2.44% |
| Vanguardindex-like | $29.3M | 4.47% | +4.16% |
| Acadian | $21.9M | 3.35% | +89.63% |
Bull1
Bear2
Expected move
No implied move.